Dr. Rhonda Bitting, MD
Claim this profileDurham VA Medical Center, Durham, NC
Studies Prostate Cancer
Studies Renal Cell Carcinoma
5 reported clinical trials
21 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
CDK12 positive
MLH1 positive
2Renal Cell Carcinoma
Stage IV
Affiliated Hospitals
Clinical Trials Rhonda Bitting, MD is currently running
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
More about Rhonda Bitting, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rhonda Bitting, MD has experience with
- Pembrolizumab
- High Dose Testosterone
- Nivolumab
- Ipilimumab
- Cabozantinib
- Carboplatin
Breakdown of trials Rhonda Bitting, MD has run
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rhonda Bitting, MD specialize in?
Rhonda Bitting, MD focuses on Prostate Cancer and Renal Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are CDK12 positive.
Is Rhonda Bitting, MD currently recruiting for clinical trials?
Yes, Rhonda Bitting, MD is currently recruiting for 4 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Rhonda Bitting, MD has studied deeply?
Yes, Rhonda Bitting, MD has studied treatments such as Pembrolizumab, High dose testosterone, Nivolumab.
What is the best way to schedule an appointment with Rhonda Bitting, MD?
Apply for one of the trials that Rhonda Bitting, MD is conducting.
What is the office address of Rhonda Bitting, MD?
The office of Rhonda Bitting, MD is located at: Durham VA Medical Center, Durham, NC, Durham, North Carolina 27705 United States. This is the address for their practice at the Durham VA Medical Center, Durham, NC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.